<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927481</url>
  </required_header>
  <id_info>
    <org_study_id>HE071-CSP-021</org_study_id>
    <nct_id>NCT04927481</nct_id>
  </id_info>
  <brief_title>A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer</brief_title>
  <official_title>A Multicenter, Open-label, Single-arm, Phase II Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, single-arm, phase II study to evaluate the safety and&#xD;
      efficacy of Mitoxantrone Hydrochloride Liposome in patients with advanced HER2 negative&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, single-arm, phase II study to evaluate the safety and&#xD;
      efficacy of Mitoxantrone Hydrochloride Liposome in patients with advanced HER2 negative&#xD;
      breast cancer. Eligible patients will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2 by&#xD;
      an intravenous infusion (IV), every 21 days (q3w, 1 cycle) until disease progression,&#xD;
      intolerable toxicity, death, or investigator or patient decision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From the enrollment to the final documentation of response of the last subject(assessed up to 36 months)</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From the enrollment to the final documentation of response of the last subject(assessed up to 36 months)</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>From the enrollment to death,lost to follow-up,withdrawal,or study end,whichever occurred first,assessed up to 36 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From the enrollment to death,lost to follow-up,withdrawal,or study end,whichever occurred first,assessed up to 36 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the enrollment to death,lost to follow-up,withdrawal,or study end,whichever occurred first,assessed up to 36 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events (TEAEs)</measure>
    <time_frame>from the administration of the first dose to 28 days after the last dose</time_frame>
    <description>The incidence and severity of adverse events, abnormalities in physical exams, vital sign assessments, clinical laboratory assessments, ultrasonic cardiograms (UCGs) and electrocardiographs (ECGs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Mitoxantrone Hydrochloride Liposome Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced HER2 negative breast cancer will receive 20 mg/m2 Mitoxantrone Hydrochloride Liposome injection every 21 days (a cycle) for about 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone Hydrochloride Liposome Injection</intervention_name>
    <description>Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).</description>
    <arm_group_label>Mitoxantrone Hydrochloride Liposome Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily participate in this study and sign informed consent form;&#xD;
&#xD;
          2. Male or female patients aged 18 to 75 years (inclusive);&#xD;
&#xD;
          3. Histologically confirmed diagnosis of HER-2 negative breast cancer (Including&#xD;
             immunohistochemistry HER2 0 or 1+, immunohistochemistry HER2 2+ must be confirmed as&#xD;
             negative by in situ hybridization);&#xD;
&#xD;
          4. Patients with unresectable locally advanced or recurrent breast cancer with disease&#xD;
             progression after first-line or higher chemotherapy；&#xD;
&#xD;
          5. Hormone receptor (HR) negative breast cancer or HR-positive breast cancer that is not&#xD;
             suitable for endocrine treatment or is resistant to endocrine treatment.&#xD;
&#xD;
          6. Prior treatment with both an anthracycline (i.e., doxorubicin or epirubicin) and a&#xD;
             taxane (i.e., paclitaxel or docetaxel) at least (acceptable for patients not&#xD;
             previously treated with anthracyclines due to high risk factors for cardiotoxicity),&#xD;
             and four prior chemotherapy regimens at most；&#xD;
&#xD;
          7. At least one measurable lesion according to RECIST v1.1;&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;&#xD;
&#xD;
          9. Patients must meet the following criteria prior to treatment (not receiving blood&#xD;
             transfusion or growth factors therapy within 14 days before the first administration):&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;&#xD;
&#xD;
               -  Hemoglobin ≥ 90g / L;&#xD;
&#xD;
               -  Platelet count ≥ 90 × 109/L;&#xD;
&#xD;
               -  Creatinine ≤1.5 × upper limit of normal (ULN);&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5×ULN;&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 ×ULN (≤ 5&#xD;
                  ×ULN for liver metastasis);&#xD;
&#xD;
         10. For women of childbearing potential: the serum pregnancy test must be negative, and&#xD;
             patients are willing to take adequate contraceptive measures during the treatment&#xD;
             period and for at least 6 months after the last dose of the study drug;&#xD;
&#xD;
         11. Good compliance and willingness to cooperate with follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have severe allergic reactions to mitoxantrone hydrochloride or liposome&#xD;
             preparation ingredients;&#xD;
&#xD;
          2. History of other malignancy within 3 years, except for radical cure of carcinoma in&#xD;
             situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin;&#xD;
&#xD;
          3. Brain metastases and meningeal metastasis;&#xD;
&#xD;
          4. Patients with active hepatitis B (HBsAg positive with hepatitis B virus DNA ≥ 2000&#xD;
             IU/mL), active hepatitis C (hepatitis C virus antibody positive with hepatitis C virus&#xD;
             RNA above the lower limit of detection of the study center), or human immunodeficiency&#xD;
             virus (HIV) antibody positive;&#xD;
&#xD;
          5. Life expectancy &lt; 3 months;&#xD;
&#xD;
          6. Previous treatment with the anthracyclines, with the total cumulative dose&#xD;
             (doxorubicin equivalent) &gt;350 mg/m2;&#xD;
&#xD;
          7. Adverse events from the previous treatment have not resolved to ≤ Grade 1 based on&#xD;
             CTCAE (except for the toxicity without safety risk judged by the investigator, such as&#xD;
             alopecia, hyperpigmentation);&#xD;
&#xD;
          8. Impaired cardiac function or serious cardiac disease:&#xD;
&#xD;
               -  Long corrected QT interval syndrome or corrected QT interval &gt; 480 ms;&#xD;
&#xD;
               -  Complete left bundle branch block, II-III degree atrioventricular block;&#xD;
&#xD;
               -  Severe, uncontrolled arrhythmias requiring pharmacological treatment;&#xD;
&#xD;
               -  History of chronic congestive heart failure, New York Heart Association ≥ grade&#xD;
                  3;&#xD;
&#xD;
               -  Cardiac ejection fraction &lt; 50% within 6 months prior to screening;&#xD;
&#xD;
               -  Heart valve disease with CTCAE ≥ grade 3;&#xD;
&#xD;
               -  ECG evidence of myocardial infarction, unstable angina, severe ventricular&#xD;
                  arrhythmias, history of severe pericardial disease, and acute ischemic or active&#xD;
                  conduction system abnormalities within 6 months prior to screening;&#xD;
&#xD;
          9. Uncontrollable hypertension (defined as a measured systolic blood pressure ≥ 160 mmHg&#xD;
             or diastolic blood pressure ≥ 100 mmHg under pharmacological control);&#xD;
&#xD;
         10. Active bacterial, fungal or viral infections that require intravenous infusion&#xD;
             treatment within 1 week prior to the first dose;&#xD;
&#xD;
         11. Any anticancer treatment (including chemotherapy, radiotherapy, molecular targeted&#xD;
             therapy, immunotherapy, endocrine therapy) within 4 weeks prior to the first dose,&#xD;
             immunomodulators as adjuvant therapy for malignancy within 2 weeks prior to the first&#xD;
             dose, any anti-tumor proprietary Chinese medicine (except for those in the category of&#xD;
             supporting and relieving symptoms) within 2 weeks prior to the first dose;&#xD;
&#xD;
         12. Patients who enrolled in any other clinical trials within 4 weeks prior to the first&#xD;
             dose;&#xD;
&#xD;
         13. Patients who undergone major surgery within 12 weeks before the first dose, or have a&#xD;
             surgical schedule during the study period;&#xD;
&#xD;
         14. Patients with thrombosis or thromboembolism within 6 months prior to screening;&#xD;
&#xD;
         15. Lactating female;&#xD;
&#xD;
         16. Serious and/or uncontrolled medical condition that, in the judgment of the&#xD;
             investigator, may affect the patient's participation in this study (including, but not&#xD;
             limited to: diabetes not effectively controlled, kidney disease requiring dialysis,&#xD;
             severe liver disease, life-threatening autoimmune and bleeding disorders, substance&#xD;
             abuse, neurological disorders, etc.);&#xD;
&#xD;
         17. Not suitable for this study as decided by the investigator due to other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>qingyuan zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yanping Liu</last_name>
    <phone>+86-10-63932012</phone>
    <email>liuyanping@mail.ecspc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincial Hospical</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yueyin pan, PhD</last_name>
      <phone>13805695536</phone>
      <email>yueyinpan1965@126.com</email>
    </contact>
    <investigator>
      <last_name>yueyin pan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center Sun Yat-sen University</name>
      <address>
        <city>Guozhou</city>
        <state>Guodong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>shusen wang, PhD</last_name>
      <phone>13926168469</phone>
      <email>wangshs@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>shusen wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>aimin zang, MD</last_name>
      <phone>13930881628</phone>
      <email>zangaimin62@sina.com</email>
    </contact>
    <investigator>
      <last_name>aimin zang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yunjiang liu, PhD</last_name>
      <phone>13703297890</phone>
      <email>lyj818326@126.com</email>
    </contact>
    <investigator>
      <last_name>yunjiang liu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tangshan People's Hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>jie ma, MD</last_name>
      <phone>13315512903</phone>
      <email>majietangshan@sina.com</email>
    </contact>
    <investigator>
      <last_name>jie Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xingtai People's Hospital</name>
      <address>
        <city>Xingtai</city>
        <state>Hebei</state>
        <zip>054000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xiangshun kong, Bechelor</last_name>
      <phone>13831920816</phone>
      <email>xtkongxiangshun@163.com</email>
    </contact>
    <investigator>
      <last_name>xiangshun kong, Bechelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qingyuan zhang</last_name>
      <phone>13313612989</phone>
      <email>sy86298276@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daqing People's Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Helongjiang</state>
        <zip>163316</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>shujuan sun, PhD</last_name>
      <phone>13604663155</phone>
      <email>Ssj9134@sohu.com</email>
    </contact>
    <investigator>
      <last_name>shujuan sun, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Jiamusi City</name>
      <address>
        <city>Jiamusi</city>
        <state>Helongjiang</state>
        <zip>154007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>hongmei sun, MD</last_name>
      <phone>15344540000</phone>
      <email>shm1357@163.com</email>
    </contact>
    <investigator>
      <last_name>hongmei sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinxiang Medical University</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ping lu, PhD</last_name>
      <phone>13598722864</phone>
      <email>lupingdoctor@126.com</email>
    </contact>
    <investigator>
      <last_name>ping lu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Henan Province</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>hongqiang guo, PhD</last_name>
      <phone>15188329236</phone>
    </contact>
    <investigator>
      <last_name>hongqiang guo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yuanting gu, PhD</last_name>
      <phone>13703844321</phone>
      <email>guyuanting2009@163.com</email>
    </contact>
    <investigator>
      <last_name>yuanting gu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhenzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zhifen luo, MD</last_name>
      <phone>13783526222</phone>
      <email>luozhifen123@126.com</email>
    </contact>
    <investigator>
      <last_name>zhifen luo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>jing cheng, PhD</last_name>
      <phone>13006178752</phone>
      <email>chenjin1118@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>jing cheng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yahua zhong, PhD</last_name>
      <phone>13207100719</phone>
      <email>doctorzyh73@163.com</email>
    </contact>
    <investigator>
      <last_name>yahua zhong, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xinhong wu, PhD</last_name>
      <phone>18602726300</phone>
      <email>xinhongwuhbch@163.com</email>
    </contact>
    <investigator>
      <last_name>xinhong wu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changsha Kexin Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>413002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yi luo, MD</last_name>
      <phone>13973119802</phone>
      <email>luoyi702@163.com</email>
    </contact>
    <investigator>
      <last_name>yi luo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yiyang Central Hospital</name>
      <address>
        <city>Yiyang</city>
        <state>Hunan</state>
        <zip>413002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>bing zhang, PhD</last_name>
      <phone>13507376227</phone>
    </contact>
    <investigator>
      <last_name>bing zhang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The third Hospital of Nanchang</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>wenyan chen, Bechelor</last_name>
      <phone>18679168977</phone>
      <email>Chenwenyannc2013@163.com</email>
    </contact>
    <investigator>
      <last_name>wenyan chen, Bechelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second hospital of Jinlin University</name>
      <address>
        <city>Changchun</city>
        <state>Jinlin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>jingwei xu, MD</last_name>
      <phone>13843193488</phone>
      <email>xjw@jlu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>jingwei xu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>man li, PhD</last_name>
      <phone>17709873573</phone>
      <email>liman126126@163.com</email>
    </contact>
    <investigator>
      <last_name>man li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinzhou Medical University</name>
      <address>
        <city>Jinzhou</city>
        <state>Liaoning</state>
        <zip>121000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zhenhua zhai, PhD</last_name>
      <phone>15941661907</phone>
      <email>zhenhua.zhai@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>zhenhua zhai, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yue'e teng, PhD</last_name>
      <phone>13591639797</phone>
      <email>tengyuee0517@163.com</email>
    </contact>
    <investigator>
      <last_name>yue'e teng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>0300001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>fuguo tian, MD</last_name>
      <phone>13934559988</phone>
    </contact>
    <investigator>
      <last_name>fuguo tian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yuncheng Central Hospital</name>
      <address>
        <city>Yuncheng</city>
        <state>Shanxi</state>
        <zip>044000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zhaofeng niu, MD</last_name>
      <phone>18035908848</phone>
      <email>18035908848@163.com</email>
    </contact>
    <investigator>
      <last_name>zhaofeng niu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital &amp; Institute</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>hao wang, PhD</last_name>
      <phone>13518204307</phone>
      <email>unique214@163.com</email>
    </contact>
    <investigator>
      <last_name>hao wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second people's hospital of neijiang</name>
      <address>
        <city>Neijiang</city>
        <state>Sichuan</state>
        <zip>641100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xujuan wang, MD</last_name>
      <phone>13696038558</phone>
    </contact>
    <investigator>
      <last_name>xujuan wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated tumor Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>bing zhao, PhD</last_name>
      <phone>13899908184</phone>
    </contact>
    <investigator>
      <last_name>bing zhao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>huarong zhao, MD</last_name>
      <phone>13899991669</phone>
      <email>xydyfyzhr@163.com</email>
    </contact>
    <investigator>
      <last_name>huarong zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

